111 related articles for article (PubMed ID: 3821428)
1. Regulatory decisions and consumers.
Rawlins MD
Med Toxicol; 1986; 1 Suppl 1():128-9. PubMed ID: 3821428
[TBL] [Abstract][Full Text] [Related]
2. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group.
Faich GA; Castle W; Bankowski Z
Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):133-8. PubMed ID: 2338366
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacovigilance: a case of phantom ships and Russian roulette].
Stricker BH
Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
[TBL] [Abstract][Full Text] [Related]
4. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
5. The role of scientific evidence of risks and benefits in determining risk management policies for medications.
Andrews E; Dombeck M
Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):599-608. PubMed ID: 15362082
[TBL] [Abstract][Full Text] [Related]
6. [Organization and results of drug vigilance in France].
Bégaud B; Chaslerie A; Haramburu F
Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
[TBL] [Abstract][Full Text] [Related]
7. Adverse drug reactions: a review of relevant factors.
Ajayi FO; Sun H; Perry J
J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
[TBL] [Abstract][Full Text] [Related]
8. Regulatory decisions. Emphasis on safety issues.
Strandberg K; Wiholm BE
Med Toxicol; 1986; 1 Suppl 1():137-49. PubMed ID: 2950292
[TBL] [Abstract][Full Text] [Related]
9. [Drug surveillance and adverse reactions to drugs. The literature and importance of historical data].
Mariani L; Minora T; Ventresca GP
Clin Ter; 1996 Dec; 147(12):653-72. PubMed ID: 9296925
[TBL] [Abstract][Full Text] [Related]
10. [International reporting of adverse drug reactions. Final report of CIOMS ADR Working Group].
Royer RJ; Benichou C
Therapie; 1991; 46(3):173-8. PubMed ID: 1792648
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing management of the use of non-narcotic analgesics.
Miettinen OS
Med Toxicol; 1986; 1 Suppl 1():125-7. PubMed ID: 3821427
[TBL] [Abstract][Full Text] [Related]
12. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
13. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
14. Short patent lives jeopardize drug and patient safety.
Hondeghem LM; De Clerck F; Camm J
J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
[TBL] [Abstract][Full Text] [Related]
15. [Adverse drug reactions definitions and terminology].
Rabinovitz H; Berkowitch M; Golik A; Shani S
Harefuah; 2001 Dec; 140(12):1181-6, 1228. PubMed ID: 11789305
[TBL] [Abstract][Full Text] [Related]
16. Post-marketing surveillance of licensed medicinal and other products.
Griffin JP
Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
[TBL] [Abstract][Full Text] [Related]
17. Research methods in drug surveillance.
Engel RR; Grohmann R; Rüther E; Hippius H
Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
[TBL] [Abstract][Full Text] [Related]
18. Regulatory decisions and the pharmaceutical industry.
Snell ES
Med Toxicol; 1986; 1 Suppl 1():130-6. PubMed ID: 3821429
[TBL] [Abstract][Full Text] [Related]
19. Current French system of post-marketing drug surveillance.
Albengres E; Gauthier F; Tillement JP
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656
[TBL] [Abstract][Full Text] [Related]
20. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
